Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review

Figure 4 Mechanisms of action of glucagon-like peptide-1 receptor agonists. Glucagon-like peptide-1 receptor agonists exert their effects by acting on the hypothalamus to increase satiety and reduce appetite, delaying gastric emptying, stimulating insulin secretion from pancreatic β-cells, and suppressing glucagon release from α-cells. These mechanisms contribute to improved glycemic control and reduced hepatic steatosis. Image adapted from Servier Medical ART (https://smart.servier.com/), licensed under CC BY 4.0 (https://creativecommons.org/Licenses/by/4.0/). GLP-1 RA: Glucagon-like peptide-1 receptor agonists; MASLD: Metabolic dysfunction-associated steatotic liver disease; TNF: Tumor necrosis factor; IL: Interleukin.